Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New...
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations...
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I...
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global...
VANCOUVER, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- Alliance Mining Corp. (TSXV:ALM) announced results from its Fall, 2021, prospecting and sampling program on its Red Rice Lake gold...
Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and...
REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG), a pioneer in providing minimally invasive treatment for patients with severe lung disease, welcomes...
BIRMINGHAM, Ala., Oct. 16 /PRNewswire-FirstCall/ -- The board of directors of Alabama Power Company (NYSE:ALM) has declared the regular quarterly dividends on the company's outstanding preferred...
RNS Number:6368U Alphameric PLC 26 January 2004 SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1) NAME OF COMPANY ALPHAMERIC PLC 2) NAME OF SHAREHOLDER HAVING A...
RNS Number:3909U Alphameric PLC 19 January 2004 SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1) NAME OF COMPANY ALPHAMERIC PLC 2) NAME OF SHAREHOLDER HAVING A MAJOR...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
